Verma S, Bhatt DL, Miller M, et al. - Significant reductions in first and recurrent ischemic events occurred in patients with a history of coronary artery bypass grafting (CABG) following treatment with icosapent ethyl.

• In REDUCE-IT, a multicenter, placebo-controlled, double-blind trial, a total of 8,179 statin-treated patients were randomized to 4g daily of icosapent ethyl or placebo.

• A history of CABG was recorded in a total of 1,837 (22.5%) patients with 897 patients randomized to icosapent ethyl and 940 to placebo.

• A significant reduction in the primary endpoint (cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina), in the key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and in total (first plus subsequent or recurrent) ischemic events occurred in correlation with randomization to icosapent ethyl vs placebo.

• Over a median follow-up time of 4.8 years, there was an absolute risk reduction of 6.2% in first events, with a number needed to treat of 16.